Merck and Roche to Jointly Promote Hepatitis C Treatment Victrelis

Merck and Roche have expanded their recent collaboration to jointly promote hepatitis C treatment Victrelis.

Merck and Roche announced Wednesday they will globally promote hepatitis C treatment Victrelis (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin (peg/riba), pending marketing approvals.

Under the expanded agreement, the companies will work together in global markets, including Europe, Asia and Latin America. The companies previously agreed to promote Victrelis in the U.S. and to explore new treatment regimens for patients with chronic HCV.

"Reaching physicians with important information about the use of Victrelis in combination with peg/riba is essential as we enter this new era in the field of chronic hepatitis C,” said Adam H. Schechter, executive vice president and president, Global Human Health, Merck. “